Establishment of a novel orthotopic xenograft model of human gallbladder carcinoma

Clinical and Experimental Metastasis

Volumn 24, Issue 3, 2007, Pages 141-148

  Egberts, Jan Hendrik ^a   Schniewind, Bodo ^a   Schafmayer, Clemens ^a   Kruse, Marie Luise ^a   Sipos, Bence ^a   Fändrich, Fred ^a   Kalthoff, Holger ^a   Tepel, Jürgen ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Cholangiocellular carcinoma; Gallbladder carcinoma; Gemcitabine; Mz ChA 1 cells; Orthotopic xenograft model

Indexed keywords

CYTOKERATIN 7; CYTOKERATIN 8; DNA FRAGMENT; GEMCITABINE; KI 67 ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; FEMALE; GALLBLADDER CARCINOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SCID MOUSE; STAINING; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; GALLBLADDER NEOPLASMS; HUMANS; KERATIN-7; KERATIN-8; KI-67 ANTIGEN; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 34249815853     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10585-007-9058-x     Document Type: Article

References (42)

1. Olnes MJ, Erlich R (2004) A review and update on cholangiocarcinoma. Oncology 66(3):167-179
2. Thongprasert S (2005) The role of chemotherapy in cholangiocarcinoma. Ann Oncol 16(suppl 2):ii93-ii96
3. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD (2005) Cholangiocarcinoma. Lancet 366(9493):1303-1314
4. Todoroki T, Ohara K, Kawamoto T, Koike N, Yoshida S, Kashiwagi H, Otsuka M et al (2000) Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys 46(3):581-587
5. Hejna M, Pruckmayer M, Raderer M (1998) The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur J Cancer 34(7):977-986
6. Knuth A, Gabbert H, Dippold W, Klein O, Sachsse W, Bitter-Suermann D, Prellwitz W et al (1985) Biliary adenocarcinoma: characterisation of three new human tumor cell lines. J Hepatol 1(6):579-596
7. Ku JL, Yoon KA, Kim IJ, Kim WH, Jang JY, Suh KS, Kim SW et al (2002) Establishment and characterisation of six human biliary tract cancer cell lines. Br J Cancer 87(2):187-193
8. Iemura A, Maruiwa M, Yano H, Kojiro M (1992) A new human cholangiocellular carcinoma cell line (KMC-1). J Hepatol 15(3):288-298
9. Emura F, Kamma H, Ghosh M, Koike N, Kawamoto T, Saijo K, Ohno T et al (2003) Establishment and characterization of novel xenograft models of human biliary tract carcinomas. Int J Oncol 23(5):1293-1300
10. Kamenz T, Caca K, Bluthner T, Tannapfel A, Mossner J, Wiedmann M (2006) Expression of c-kit receptor in human cholangiocarcinoma and in vivo treatment with imatinib mesilate in chimeric mice. World J Gastroenterol 12(10):1583-1590
11. Gohongi T, Todoroki T, Fukumura D, Jain RK (2004) Influence of the site of human gallbladder xenograft (Mz-ChA-1) on angiogenesis at the distant site. Oncol Rep 11(4):803-807
12. Horiuchi H, Kawamata H, Fujimori T, Kuroda Y (2003) A MEK inhibitor (U0126) prolongs survival in nude mice bearing human gallbladder cancer cells with K-ras mutation: analysis in a novel orthotopic inoculation model. Int J Oncol 23(4):957-963
13. Park JS, Oh SY, Kim SH, Kwon HC, Kim JS, Jin-Kim H, Kim YH (2005) Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Jpn J Clin Oncol 35(2):68-73
14. Gebbia V, Giuliani F, Maiello E, Colucci G, Verderame F, Borsellino N, Mauceri G et al (2001) Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol 19(20):4089-4091
15. Tsavaris N, Kosmas C, Gouveris P, Gennatas K, Polyzos A, Mouratidou D, Tsipras H et al (2004) Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs 22(2):193-198
16. Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Lenauer A, Depisch D et al (2001) Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 12(2):183-186
17. Tomayko MM, Reynolds CP (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24(3):148-154
18. West J, Wood H, Logan RF, Quinn M, Aithal GP (2006) Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer 94(11):1751-1758
19. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC (2002) Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 37(6):806-813
20. Patel T (2002) Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2:10
21. Alberts SR, Al-Khatib H, Mahoney MR, Burgart L, Cera PJ, Flynn PJ, Finch TR et al (2005) Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer 103(1):111-118
22. Radaeva S, Ferreira-Gonzalez A, Sirica AE (1999) Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: a link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma. Hepatology 29(5):1453-1462
23. Elmore LW, Sirica AE (1993) "Intestinal-type" of adenocarcinoma preferentially induced in right/caudate liver lobes of rats treated with furan. Cancer Res 53(2):254-259
24. Sirica AE (1996) Biliary proliferation and adaptation in furan-induced rat liver injury and carcinogenesis. Toxicol Pathol 24(1):90-99
25. Thamavit W, Pairojkul C, Tiwawech D, Itoh M, Shirai T, Ito N (1993) Promotion of cholangiocarcinogenesis in the hamster liver by bile duct ligation after dimethylnitrosamine initiation. Carcinogenesis 14(11):2415-2417
26. Iki K, Tsujiuchi T, Majima T, Sakitani H, Tsutsumi M, Takahama M, Yoshimoto M et al (1998) Increased telomerase activity in intrahepatic cholangiocellular carcinomas induced by N-nitrosobis(2-oxopropyl)amine in hamsters. Cancer Lett 131(2):185-190
27. Tengchaisri T, Prempracha N, Thamavit W, Boonpucknavig S, Sriurairatana S, Sirisinha S (1995) Establishment and characterization of cell lines from liver fluke-associated cholangiocarcinoma induced in a hamster model. Southeast Asian J Trop Med Public Health 26(2):231-239
28. Tesana S, Takahashi Y, Sithithaworn P, Ando K, Sakakura T, Yutanawiboonchai W, Pairojkul C et al (2000) Ultrastructural and immunohistochemical analysis of cholangiocarcinoma in immunized Syrian golden hamsters infected with Opisthorchis viverrini and administered with dimethylnitrosamine. Parasitol Int 49(3):239-251
29. Imray CH, Newbold KM, Davis A, Lavelle-Jones M, Neoptolemos JP (1992) Induction of cholangiocarcinoma in the Golden Syrian hamster using methylazoxymethyl acetate. Eur J Surg Oncol 18(4):373-378
30. Kiguchi K, Carbajal S, Chan K, Beltran L, Ruffino L, Shen J, Matsumoto T et al (2001) Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res 61(19):6971-6976
31. Yamaguchi N, Morioka H, Ohkura H, Hirohashi S, Kawai K (1985) Establishment and characterization of the human cholangiocarcinoma cell line HChol-Y1 in a serum-free, chemically defined medium. J Natl Cancer Inst 75(1):29-35
32. Shimizu Y, Demetris AJ, Gollin SM, Storto PD, Bedford HM, Altarac S, Iwatsuki S et al (1992) Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. Int J Cancer 52(2):252-260
33. Tsubono M, Nio Y, Tseng CC, Kawabata K, Masai Y, Hayashi H, Fukumoto M et al (1992) Experimental chemotherapy for xenograft cell lines of human bile duct and gall bladder cancers in nude mice. J Surg Oncol 51(4):274-280
34. Wiedmann M, Feisthammel J, Bluthner T, Tannapfel A, Kamenz T, Kluge A, Mossner J et al (2006) Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anticancer Drugs 17(7):783-795
35. Gohongi T, Fukumura D, Boucher Y, Yun CO, Soff GA, Compton C, Todoroki T et al (1999) Tumor-host interactions in the gallbladder suppress distal angiogenesis and tumor growth: involvement of transforming growth factor beta1. Nat Med 5(10):1203-1208
36. Fava G, Marucci L, Glaser S, Francis H, De Morrow S, Benedetti A, Alvaro D et al (2005) Gamma-aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway. Cancer Res 65(24):11437-11446
37. Date K, Matsumoto K, Kuba K, Shimura H, Tanaka M, Nakamura T (1998) Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene 17(23):3045-3054
38. Nishime C, Ohnishi Y, Suemizu H, Tamaoki N, Suematsu M, Oida Y, Yamazaki H et al (2006) Gallbladder small cell carcinoma Xenograft established by serial transplantation in nude mice. Anticancer Res 26(1A):79-83
39. Doctor RB, Matzakos T, McWilliams R, Johnson S, Feranchak AP, Fitz JG (2005) Purinergic regulation of cholangiocyte secretion: identification of a novel role for P2X receptors. Am J Physiol Gastrointest Liver Physiol 288(4):G779-G786
40. Marienfeld C, Tadlock L, Yamagiwa Y, Patel T (2003) Inhibition of cholangiocarcinoma growth by tannic acid. Hepatology 37(5):1097-1104
41. Roman RM, Bodily KO, Wang Y, Raymond JR, Fitz JG (1998) Activation of protein kinase Calpha couples cell volume to membrane Cl-permeability in HTC hepatoma and Mz-ChA-1 cholangiocarcinoma cells. Hepatology 28(4):1073-1080
42. Kwiatkowski AP, McGill JM (1995) Human biliary epithelial cell line Mz-ChA-1 expresses new isoforms of calmodulin-dependent protein kinase II. Gastroenterology 109(4):1316-1323